Positron emission tomography molecular imaging in late-life depression

Journal of Geriatric Psychiatry and Neurology

Volumn 27, Issue 1, 2014, Pages 13-23

  Hirao, Kentaro ^a,b   Smith, Gwenn S ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b TOKYO MEDICAL UNIVERSITY   (Japan)

Author keywords

acetylcholine; depression; dopamine; molecular imaging; positron emission tomography; serotonin

Indexed keywords

4 AMINOBUTYRIC ACID; AMYLOID BETA PROTEIN; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; MUSCARINIC M2 RECEPTOR; SEROTONIN 1A RECEPTOR; SEROTONIN 2 RECEPTOR;

ANTERIOR CINGULATE; ARTICLE; BRAIN ATROPHY; BRAIN BLOOD FLOW; BRAIN METABOLISM; BRAIN SIZE; CAUDATE NUCLEUS; CEREBELLUM; CEREBROSPINAL FLUID; CINGULATE GYRUS; COGNITION; COMORBIDITY; CORPUS STRIATUM; DEPRESSIVE PSYCHOSIS; DOPAMINE BRAIN LEVEL; DOPAMINERGIC SYSTEM; DORSAL RAPHE NUCLEUS; FRONTAL CORTEX; FRONTAL LOBE; GABAERGIC SYSTEM; GENETICS; GERIATRIC PATIENT; GLUCOSE METABOLISM; HEAD MOVEMENT; HUMAN; IMAGE PROCESSING; INFLAMMATION; INSULA; LATE LIFE DEPRESSION; LEFT HEMISPHERE; MAJOR DEPRESSION; MANIA; MESENCEPHALON; MIDDLE FRONTAL GYRUS; MOLECULAR IMAGING; MONOAMINERGIC SYSTEM; NEUROBIOLOGY; NEUROCHEMISTRY; NEUROIMAGING; NEUROPATHOLOGY; NEUROPSYCHIATRY; NONHUMAN; ORBITAL CORTEX; PARAHIPPOCAMPAL GYRUS; PARIETAL LOBE; POSITRON EMISSION TOMOGRAPHY; POSTERIOR CINGULATE; PRIORITY JOURNAL; RADIOACTIVITY; SENSORIMOTOR CORTEX; SEROTONIN BRAIN LEVEL; SEROTONINERGIC SYSTEM; SUPERIOR FRONTAL GYRUS; TEMPORAL CORTEX; TEMPORAL LOBE; THALAMUS;

ACETYLCHOLINE; DEPRESSION; DOPAMINE; MOLECULAR IMAGING; POSITRON EMISSION TOMOGRAPHY; SEROTONIN;

ACETYLCHOLINE; AGE OF ONSET; BRAIN; DEPRESSION; DOPAMINE; HUMANS; MOLECULAR IMAGING; NEUROIMAGING; POSITRON-EMISSION TOMOGRAPHY; RECEPTORS, SEROTONIN;

EID: 84893562851     PISSN: 08919887     EISSN: 15525708     Source Type: Journal    
DOI: 10.1177/0891988713516540     Document Type: Article

References (127)

1. Phelps M, Mazziotta J, Schelbert H Positron emission tomography and autoradiography: principles and applications for the brain and heart. New York: Raven Press ; 1986: 237-286.
2. Bailey D, Townsend D, Valk P, Maisey M Positron emission tomography. Basic Science. United States: Springer ; 2005 :
3. Shao X, Hoareau R, Hockley BG, et al. Highlighting the versatility of the tracerlab synthesis modules. part 1: fully automated production of [F]labelled radiopharmaceuticals using a tracerlab FX(FN). J Labelled Comp Radiopharm. 2011 ; 54 (6). 292-307
4. Ferris SH, de Leon MJ, Wolf AP, et al. Positron emission tomography in dementia. Adv Neurol. 1983 ; 38: 123-129
5. Giovacchini G, Squitieri F, Esmaeilzadeh M, Milano A, Mansi L, Ciarmiello A. PET translates neurophysiology into images: A review to stimulate a network between neuroimaging and basic research. J Cell Physiol. 2011 ; 226 (4). 948-961
6. Kumar A. Functional brain imaging in late-life depression and dementia. J Clin Psychiatry. 1993 ; 54 (suppl). 21-25
7. Buchsbaum MS, Ingvar DH, Kessler R, et al. Cerebral glucography with positron tomography. use in normal subjects and in patients with schizophrenia. Arch Gen Psychiatry. 1982 ; 39 (3). 251-259
8. Phelps ME, Mazziotta JC, Baxter L, Gerner R. Positron emission tomographic study of affective disorders: Problems and strategies. Ann Neurol. 1984 ; 15 (suppl). S149 - S156
9. Baxter LR, Phelps ME, Mazziotta JC, Guze BH, Schwartz JM, Selin CE. Local cerebral glucose metabolic rates in obsessive-compulsive disorder. a comparison with rates in unipolar depression and in normal controls. Arch Gen Psychiatry. 1987 ; 44 (3). 211-218
10. Wagner HN, Burns HD, Dannals RF, et al. Imaging dopamine receptors in the human brain by positron tomography. Science. 1983 ; 221 (4617). 1264-1266
11. Arnett CD, Wolf AP, Shiue CY, et al. Improved delineation of human dopamine receptors using [18F]-N-methylspiroperidol and PET. J Nucl Med. 1986 ; 27 (12). 1878-1882
12. Booij J, van Amelsvoort T. Imaging as tool to investigate psychoses and antipsychotics. Handb Exp Pharmacol. 2012 ; (212). 299-337
13. Wong DF, Tauscher J, Grunder G. The role of imaging in proof of concept for CNS drug discovery and development. Neuropsychopharmacology. 2009 ; 34 (1). 187-203
14. Sacher J, Smith G Imaging Neuropsychiatric Disorders. Turetsky B Shenton M, ed. New York: Cambridge University Press: ; 2011: 170-196.
15. Chauveau F, Boutin H, Van Camp N, Dolle F, Tavitian B. Nuclear imaging of neuroinflammation: a comprehensive review of [11C]PK11195 challengers. Eur J Nucl Med Mol Imaging. 2008 ; 35 (12). 2304-2319
16. Mathis CA, Wang Y, Holt DP, Huang GF, Debnath ML, Klunk WE. Synthesis and evaluation of 11C-labeled 6-substituted 2-arylbenzothiazoles as amyloid imaging agents. J Med Chem. 2003 ; 46 (13). 2740-2754
17. Chien DT, Bahri S, Szardenings AK, et al. Early clinical PET imaging results with the novel PHF-tau radioligand [F-18]-T807. J Alzheimers Dis. 2013 ; 34 (2). 457-468
18. Neal KL, Shakerdge NB, Hou SS, et al. Development and screening of contrast agents for in vivo imaging of parkinson's disease. Mol Imaging Biol. 2013 ; 15 (5). 585-595
19. Wienhard K. Measurement of glucose consumption using [(18)F] fluorodeoxyglucose. Methods. 2002 ; 27 (3). 218-225
20. Townsend DW. Multimodality imaging of structure and function. Phys Med Biol. 2008 ; 53 (4). R1 - R39
21. Wehrl HF, Sauter AW, Judenhofer MS, Pichler BJ. Combined PET/MR imaging - technology and applications. Technol Cancer Res Treat. 2010 ; 9 (1). 5-20
22. Rousset OG, Collins DL, Rahmim A, Wong DF. Design and implementation of an automated partial volume correction in PET: Application to dopamine receptor quantification in the normal human striatum. J Nucl Med. 2008 ; 49 (7). 1097-1106
23. Shidahara M, Tsoumpas C, Hammers A, et al. Functional and structural synergy for resolution recovery and partial volume correction in brain PET. Neuroimage. 2009 ; 44 (2). 340-348
24. Montgomery AJ, Thielemans K, Mehta MA, Turkheimer F, Mustafovic S, Grasby PM. Correction of head movement on PET studies: comparison of methods. J Nucl Med. 2006 ; 47 (12). 1936-1944
25. Rahmim A, Dinelle K, Cheng JC, et al. Accurate event-driven motion compensation in high-resolution PET incorporating scattered and random events. IEEE Trans Med Imaging. 2008 ; 27 (8). 1018-1033
26. Mayberg HS. Modulating dysfunctional limbic-cortical circuits in depression: towards development of brain-based algorithms for diagnosis and optimised treatment. Br Med Bull. 2003 ; 65: 193-207
27. Fitzgerald PB, Laird AR, Maller J, Daskalakis ZJ. A meta-analytic study of changes in brain activation in depression. Hum Brain Mapp. 2008 ; 29 (6). 683-695
28. Savitz JB, Drevets WC. Neuroreceptor imaging in depression. Neurobiol Dis. 2013 ; 52: 49-65
29. Kumar A, Newberg A, Alavi A, Berlin J, Smith R, Reivich M. Regional cerebral glucose metabolism in late-life depression and Alzheimer disease: A preliminary positron emission tomography study. Proc Natl Acad Sci U S A. 1993 ; 90 (15). 7019-7023
30. Nobler MS, Roose SP, Prohovnik I, et al. Regional cerebral blood flow in mood disorders, V.: Effects of antidepressant medication in late-life depression. Am J Geriatr Psychiatry. 2000 ; 8 (4). 289-296
31. Smith GS, Reynolds CF, Pollock B, et al. Cerebral glucose metabolic response to combined total sleep deprivation and antidepressant treatment in geriatric depression. Am J Psychiatry. 1999 ; 156 (5). 683-689
32. Smith GS, Kramer E, Hermann CR, et al. Acute and chronic effects of citalopram on cerebral glucose metabolism in geriatric depression. Am J Geriatr Psychiatry. 2002 ; 10 (6). 715-723
33. Smith GS, Reynolds CF, Houck PR, et al. Cerebral glucose metabolic response to combined total sleep deprivation and antidepressant treatment in geriatric depression: a randomized, placebo-controlled study. Psychiatry Res. 2009 ; 171 (1). 1-9
34. Smith GS, Kramer E, Ma Y, et al. The functional neuroanatomy of geriatric depression. Int J Geriatr Psychiatry. 2009 ; 24 (8). 798-808
35. Smith GS, Reynolds CF, Houck PR, et al. Glucose metabolic response to total sleep deprivation, recovery sleep, and acute antidepressant treatment as functional neuroanatomic correlates of treatment outcome in geriatric depression. Am J Geriatr Psychiatry. 2002 ; 10 (5). 561-567
36. Diaconescu AO, Kramer E, Hermann C, et al. Distinct functional networks associated with improvement of affective symptoms and cognitive function during citalopram treatment in geriatric depression. Hum Brain Mapp. 2011 ; 32 (10). 1677-1691
37. Smith GS, Workman CI, Kramer E, et al. The relationship between the acute cerebral metabolic response to citalopram and chronic citalopram treatment outcome. Am J Geriatr Psychiatry. 2011 ; 19 (1). 53-63
38. Buckner RL, Snyder AZ, Shannon BJ, et al. Molecular, structural, and functional characterization of Alzheimer's disease: evidence for a relationship between default activity, amyloid, and memory. J Neurosci. 2005 ; 25 (34). 7709-7717
39. Schildkraut JJ. The catecholamine hypothesis of affective disorders: a review of supporting evidence. Am J Psychiatry. 1965 ; 122 (5). 509-522
40. Lapin IP, Oxenkrug GF. Intensification of the central serotoninergic processes as a possible determinant of the thymoleptic effect. Lancet. 1969 ; 1 (7586). 132-136
41. Brown AS, Gershon S. Dopamine and depression. J Neural Transm Gen Sect. 1993 ; 91 (2-3). 75-109
42. Nestler EJ, Carlezon WA. The mesolimbic dopamine reward circuit in depression. Biol Psychiatry. 2006 ; 59 (12). 1151-1159
43. Klimek V, Schenck JE, Han H, Stockmeier CA, Ordway GA. Dopaminergic abnormalities in amygdaloid nuclei in major depression: a postmortem study. Biol Psychiatry. 2002 ; 52 (7). 740-748
44. Bowden C, Theodorou AE, Cheetham SC, et al. Dopamine D1 and D2 receptor binding sites in brain samples from depressed suicides and controls. Brain Res. 1997 ; 752 (1-2). 227-233
45. Agren H, Reibring L. PET studies of presynaptic monoamine metabolism in depressed patients and healthy volunteers. Pharmacopsychiatry. 1994 ; 27 (1). 2-6
46. Meyer JH, Kruger S, Wilson AA, et al. Lower dopamine transporter binding potential in striatum during depression. Neuroreport. 2001 ; 12 (18). 4121-4125
47. Suhara T, Nakayama K, Inoue O, et al. D1 dopamine receptor binding in mood disorders measured by positron emission tomography. Psychopharmacology (Berl). 1992 ; 106 (1). 14-18
48. Cannon DM, Klaver JM, Peck SA, Rallis Voak D, Erickson K, Drevets WC. Dopamine type-1 receptor binding in major depressive disorder assessed using positron emission tomography and [11C]NNC-112. Neuropsychopharmacology. 2009 ; 34 (5). 1277-1287
49. Klimke A, Larisch R, Janz A, Vosberg H, Muller-Gartner HW, Gaebel W. Dopamine D2 receptor binding before and after treatment of major depression measured by [123I]IBZM SPECT. Psychiatry Res. 1999 ; 90 (2). 91-101
50. Parsey RV, Oquendo MA, Zea-Ponce Y, et al. Dopamine D(2) receptor availability and amphetamine-induced dopamine release in unipolar depression. Biol Psychiatry. 2001 ; 50 (5). 313-322
51. Hirvonen J, Karlsson H, Kajander J, et al. Striatal dopamine D2 receptors in medication-naive patients with major depressive disorder as assessed with [11C]raclopride PET. Psychopharmacology (Berl). 2008 ; 197 (4). 581-590
52. Montgomery AJ, Stokes P, Kitamura Y, Grasby PM. Extrastriatal D2 and striatal D2 receptors in depressive illness: pilot PET studies using [11C]FLB 457 and [11C]raclopride. J Affect Disord. 2007 ; 101 (1-3). 113-122
53. Meyer JH, McNeely HE, Sagrati S, et al. Elevated putamen D(2) receptor binding potential in major depression with motor retardation: An [11C]raclopride positron emission tomography study. Am J Psychiatry. 2006 ; 163 (9). 1594-1602
54. Anand A, Verhoeff P, Seneca N, et al. Brain SPECT imaging of amphetamine-induced dopamine release in euthymic bipolar disorder patients. Am J Psychiatry. 2000 ; 157 (7). 1108-1114
55. Volkow ND, Gur RC, Wang GJ, et al. Association between decline in brain dopamine activity with age and cognitive and motor impairment in healthy individuals. Am J Psychiatry. 1998 ; 155 (3). 344-349
56. Volkow ND, Wang GJ, Fowler JS, et al. Parallel loss of presynaptic and postsynaptic dopamine markers in normal aging. Ann Neurol. 1998 ; 44 (1). 143-147
57. Lavretsky H, Kumar A. Methylphenidate augmentation of citalopram in elderly depressed patients. Am J Geriatr Psychiatry. 2001 ; 9 (3). 298-303
58. Mann JJ. Role of the serotonergic system in the pathogenesis of major depression and suicidal behavior. Neuropsychopharmacology. 1999 ; 21 (2 suppl). 99S - 105S
59. Owens MJ, Nemeroff CB. The serotonin transporter and depression. Depress Anxiety. 1998 ; 8 (suppl 1). 5-12
60. McKeith IG, Marshall EF, Ferrier IN, et al. 5-HT receptor binding in post-mortem brain from patients with affective disorder. J Affect Disord. 1987 ; 13 (1). 67-74
61. Arango V, Ernsberger P, Marzuk PM, et al. Autoradiographic demonstration of increased serotonin 5-HT2 and beta-adrenergic receptor binding sites in the brain of suicide victims. Arch Gen Psychiatry. 1990 ; 47 (11). 1038-1047
62. Stockmeier CA, Shapiro LA, Dilley GE, Kolli TN, Friedman L, Rajkowska G. Increase in serotonin-1A autoreceptors in the midbrain of suicide victims with major depression-postmortem evidence for decreased serotonin activity. J Neurosci. 1998 ; 18 (18). 7394-7401
63. Thomas AJ, Hendriksen M, Piggott M, et al. A study of the serotonin transporter in the prefrontal cortex in late-life depression and Alzheimer's disease with and without depression. Neuropathol Appl Neurobiol. 2006 ; 32 (3). 296-303
64. Agren H, Reibring L, Hartvig P, et al. Low brain uptake of L-[11C]5-hydroxytryptophan in major depression: a positron emission tomography study on patients and healthy volunteers. Acta Psychiatr Scand. 1991 ; 83 (6). 449-455
65. Rosa-Neto P, Diksic M, Okazawa H, et al. Measurement of brain regional alpha-[11C]methyl-L-tryptophan trapping as a measure of serotonin synthesis in medication-free patients with major depression. Arch Gen Psychiatry. 2004 ; 61 (6). 556-563
66. Cannon DM, Ichise M, Fromm SJ, et al. Serotonin transporter binding in bipolar disorder assessed using [11C]DASB and positron emission tomography. Biol Psychiatry. 2006 ; 60 (3). 207-217
67. Cannon DM, Ichise M, Rollis D, et al. Elevated serotonin transporter binding in major depressive disorder assessed using positron emission tomography and [11C]DASB; comparison with bipolar disorder. Biol Psychiatry. 2007 ; 62 (8). 870-877
68. Reimold M, Batra A, Knobel A, et al. Anxiety is associated with reduced central serotonin transporter availability in unmedicated patients with unipolar major depression: A [11C]DASB PET study. Mol Psychiatry. 2008 ; 13 (6). 606-13
69. Miller JM, Oquendo MA, Ogden RT, Mann JJ, Parsey RV. Serotonin transporter binding as a possible predictor of one-year remission in major depressive disorder. J Psychiatr Res. 2008 ; 42 (14). 1137-1144
70. Parsey RV, Kent JM, Oquendo MA, et al. Acute occupancy of brain serotonin transporter by sertraline as measured by [11C]DASB and positron emission tomography. Biol Psychiatry. 2006 ; 59 (9). 821-828
71. Bhagwagar Z, Murthy N, Selvaraj S, et al. 5-HTT binding in recovered depressed patients and healthy volunteers: a positron emission tomography study with [11C]DASB. Am J Psychiatry. 2007 ; 164 (12). 1858-1865
72. Meyer JH, Houle S, Sagrati S, et al. Brain serotonin transporter binding potential measured with carbon 11-labeled DASB positron emission tomography: effects of major depressive episodes and severity of dysfunctional attitudes. Arch Gen Psychiatry. 2004 ; 61 (12). 1271-1279
73. Kugaya A, Sanacora G, Staley JK, et al. Brain serotonin transporter availability predicts treatment response to selective serotonin reuptake inhibitors. Biol Psychiatry. 2004 ; 56 (7). 497-502
74. Meyer JH, Wilson AA, Ginovart N, et al. Occupancy of serotonin transporters by paroxetine and citalopram during treatment of depression: A [(11)C]DASB PET imaging study. Am J Psychiatry. 2001 ; 158 (11). 1843-1849
75. Smith GS, Kahn A, Sacher J, et al. Serotonin transporter occupancy and the functional neuroanatomic effects of citalopram in geriatric depression. Am J Geriatr Psychiatry. 2011 ; 19 (12). 1016-1025
76. Smith GS, Kramer E, Hermann C, et al. Serotonin modulation of cerebral glucose metabolism in depressed older adults. Biol Psychiatry. 2009 ; 66 (3). 259-266
77. Drevets WC, Frank E, Price JC, et al. PET imaging of serotonin 1A receptor binding in depression. Biol Psychiatry. 1999 ; 46 (10). 1375-1387
78. Sargent PA, Kjaer KH, Bench CJ, et al. Brain serotonin1A receptor binding measured by positron emission tomography with [11C]WAY-100635: Effects of depression and antidepressant treatment. Arch Gen Psychiatry. 2000 ; 57 (2). 174-180
79. Hirvonen J, Karlsson H, Kajander J, et al. Decreased brain serotonin 5-HT1A receptor availability in medication-naive patients with major depressive disorder: An in-vivo imaging study using PET and [carbonyl-11C]WAY-100635. Int J Neuropsychopharmacol. 2008 ; 11 (4). 465-476
80. Parsey RV, Oquendo MA, Ogden RT, et al. Altered serotonin 1A binding in major depression: A [carbonyl-C-11]WAY100635 positron emission tomography study. Biol Psychiatry. 2006 ; 59 (2). 106-113
81. Parsey RV, Olvet DM, Oquendo MA, Huang YY, Ogden RT, Mann JJ. Higher 5-HT1A receptor binding potential during a major depressive episode predicts poor treatment response: preliminary data from a naturalistic study. Neuropsychopharmacology. 2006 ; 31 (8). 1745-1749
82. Moses Kolko EL, Price JC, Thase ME, et al. Measurement of 5-HT1A receptor binding in depressed adults before and after antidepressant drug treatment using positron emission tomography and [11C]WAY-100635. Synapse. 2007 ; 61 (7). 523-530
83. Meltzer CC, Price JC, Mathis CA, et al. Serotonin 1A receptor binding and treatment response in late-life depression. Neuropsychopharmacology. 2004 ; 29 (12). 2258-2265
84. Blier P, De Montigny C, Azzaro AJ. Modification of serotonergic and noradrenergic neurotransmissions by repeated administration of monoamine oxidase inhibitors: electrophysiological studies in the rat central nervous system. J Pharmacol Exp Ther. 1986 ; 237 (3). 987-994
85. Meyer JH, Kapur S, Eisfeld B, et al. The effect of paroxetine on 5-HT(2A) receptors in depression: an [(18)F]setoperone PET imaging study. Am J Psychiatry. 2001 ; 158 (1). 78-85
86. Meltzer CC, Price JC, Mathis CA, et al. PET imaging of serotonin type 2A receptors in late-life neuropsychiatric disorders. Am J Psychiatry. 1999 ; 156 (12). 1871-1878
87. Biver F, Wikler D, Lotstra F, Damhaut P, Goldman S, Mendlewicz J. Serotonin 5-HT2 receptor imaging in major depression: Focal changes in orbito-insular cortex. Br J Psychiatry. 1997 ; 171: 444-448
88. Sheline YI, Mintun MA, Barch DM, Wilkins C, Snyder AZ, Moerlein SM. Decreased hippocampal 5-HT(2A) receptor binding in older depressed patients using [18F]altanserin positron emission tomography. Neuropsychopharmacology. 2004 ; 29 (12). 2235-2241
89. Meyer JH, Kapur S, Houle S, et al. Prefrontal cortex 5-HT2 receptors in depression: An [18F]setoperone PET imaging study. Am J Psychiatry. 1999 ; 156 (7). 1029-1034
90. Bhagwagar Z, Hinz R, Taylor M, Fancy S, Cowen P, Grasby P. Increased 5-HT(2A) receptor binding in euthymic, medication-free patients recovered from depression: a positron emission study with [(11)C]MDL 100,907. Am J Psychiatry. 2006 ; 163 (9). 1580-1587
91. Yatham LN, Liddle PF, Dennie J, et al. Decrease in brain serotonin 2 receptor binding in patients with major depression following desipramine treatment: a positron emission tomography study with fluorine-18-labeled setoperone. Arch Gen Psychiatry. 1999 ; 56 (8). 705-711
92. Moresco RM, Colombo C, Fazio F, et al. Effects of fluvoxamine treatment on the in vivo binding of [F-18]FESP in drug naive depressed patients: a PET study. Neuroimage. 2000 ; 12 (4). 452-465
93. Massou JM, Trichard C, Attar-Levy D, et al. Frontal 5-HT2A receptors studied in depressive patients during chronic treatment by selective serotonin reuptake inhibitors. Psychopharmacology (Berl). 1997 ; 133 (1). 99-101
94. Cannon DM, Carson RE, Nugent AC, et al. Reduced muscarinic type 2 receptor binding in subjects with bipolar disorder. Arch Gen Psychiatry. 2006 ; 63 (7). 741-747
95. Drevets WC, Zarate CA, Furey ML. Antidepressant effects of the muscarinic cholinergic receptor antagonist scopolamine: a review. Biol Psychiatry. 2013 ; 73 (12). 1156-1163
96. Zarate CA, Singh JB, Carlson PJ, et al. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry. 2006 ; 63 (8). 856-864
97. Kendell SF, Krystal JH, Sanacora G. GABA and glutamate systems as therapeutic targets in depression and mood disorders. Expert Opin Ther Targets. 2005 ; 9 (1). 153-168
98. Hasler G, van der Veen JW, Tumonis T, Meyers N, Shen J, Drevets WC. Reduced prefrontal glutamate/glutamine and gamma-aminobutyric acid levels in major depression determined using proton magnetic resonance spectroscopy. Arch Gen Psychiatry. 2007 ; 64 (2). 193-200
99. Deschwanden A, Karolewicz B, Feyissa AM, et al. Reduced metabotropic glutamate receptor 5 density in major depression determined by [(11)C]ABP688 PET and postmortem study. Am J Psychiatry. 2011 ; 168 (7). 727-734
100. Machado-Vieira R, Salvadore G, Diazgranados N, Zarate CA. Ketamine and the next generation of antidepressants with a rapid onset of action. Pharmacol Ther. 2009 ; 123 (2). 143-150
101. Brambilla P, Perez J, Barale F, Schettini G, Soares JC. GABAergic dysfunction in mood disorders. Mol Psychiatry. 2003 ; 8 (8). 721-37
102. Zarate CA, Du J, Quiroz J, et al. Regulation of cellular plasticity cascades in the pathophysiology and treatment of mood disorders: role of the glutamatergic system. Ann N Y Acad Sci. 2003 ; 1003: 273-291
103. Khundakar A, Morris C, Thomas AJ. The immunohistochemical examination of GABAergic interneuron markers in the dorsolateral prefrontal cortex of patients with late-life depression. Int Psychogeriatr. 2011 ; 23 (4). 644-653
104. Richardson JS, Miller PS, Lemay JS, et al. Mental dysfunction and the blockade of muscarinic receptors in the brains of the normal elderly. Prog Neuropsychopharmacol Biol Psychiatry. 1985 ; 9 (5-6). 651-654
105. Sweet RA, Hamilton RL, Butters MA, et al. Neuropathologic correlates of late-onset major depression. Neuropsychopharmacology. 2004 ; 29 (12). 2242-2250
106. Tsopelas C, Stewart R, Savva GM, et al. Neuropathological correlates of late-life depression in older people. Br J Psychiatry. 2011 ; 198 (2). 109-114
107. Khundakar AA, Thomas AJ Am J Geriatr Psychiatry. 2013 :
108. Butters MA, Klunk WE, Mathis CA, et al. Imaging Alzheimer pathology in late-life depression with PET and pittsburgh compound-B. Alzheimer Dis Assoc Disord. 2008 ; 22 (3). 261-268
109. Marano CM, Workman Cl, Lyman CH, et al. Cortical beta-amyloid deposition in late-life depression. Am J Geriatr Psychiatry. 2013 ; 21 (3). 127
110. Kumar A, Kepe V, Barrio JR, et al. Protein binding in patients with late-life depression. Arch Gen Psychiatry. 2011 ; 68 (11). 1143-1150
111. Lavretsky H, Siddarth P, Kepe V, et al. Depression and anxiety symptoms are associated with cerebral FDDNP-PET binding in middle-aged and older nondemented adults. Am J Geriatr Psychiatry. 2009 ; 17 (6). 493-502
112. Smith GS, Gunning-Dixon FM, Lotrich FE, Taylor WD, Evans JD. Translational research in late-life mood disorders: Implications for future intervention and prevention research. Neuropsychopharmacology. 2007 ; 32 (9). 1857-1875
113. Zhu CB, Blakely RD, Hewlett WA. The proinflammatory cytokines interleukin-1beta and tumor necrosis factor-alpha activate serotonin transporters. Neuropsychopharmacology. 2006 ; 31 (10). 2121-2131
114. Lopresti AL, Maker GL, Hood SD, Drummond PD. A review of peripheral biomarkers in major depression: the potential of inflammatory and oxidative stress biomarkers. Prog Neuropsychopharmacol Biol Psychiatry. 2013 ; 48C: 102-111
115. Hannestad J, Dellagioia N, Gallezot JD, et al. The neuroinflammation marker translocator protein is not elevated in individuals with mild-to-moderate depression: a [(11)C]PBR28 PET study. Brain Behav Immun. 2013 ; 33: 131-138
116. Thomas AJ, O'Brien JT, Davis S, et al. Ischemic basis for deep white matter hyperintensities in major depression: a neuropathological study. Arch Gen Psychiatry. 2002 ; 59 (9). 785-792
117. Pierson ME, Andersson J, Nyberg S, et al. [11C]AZ10419369: A selective 5-HT1B receptor radioligand suitable for positron emission tomography (PET). Characterization in the primate brain. Neuroimage. 2008 ; 41 (3). 1075-1085
118. Marner L, Gillings N, Comley RA, et al. Kinetic modeling of 11C-SB207145 binding to 5-HT4 receptors in the human brain in vivo. J Nucl Med. 2009 ; 50 (6). 900-908
119. Parker CA, Gunn RN, Rabiner EA, et al. Radiosynthesis and characterization of 11C-GSK215083 as a PET radioligand for the 5-HT6 receptor. J Nucl Med. 2012 ; 53 (2). 295-303
120. Ding YS, Singhal T, Planeta-Wilson B, et al. PET imaging of the effects of age and cocaine on the norepinephrine transporter in the human brain using (S, S)-[(11)C]O-methylreboxetine and HRRT. Synapse. 2010 ; 64 (1). 30-38
121. Mathew SJ, Manji HK, Charney DS. Novel drugs and therapeutic targets for severe mood disorders. Neuropsychopharmacology. 2008 ; 33 (9). 2080-2092
122. Furey ML, Drevets WC. Antidepressant efficacy of the antimuscarinic drug scopolamine: a randomized, placebo-controlled clinical trial. Arch Gen Psychiatry. 2006 ; 63 (10). 1121-1129
123. Ondrejcak T, Klyubin I, Hu NW, Barry AE, Cullen WK, Rowan MJ. Alzheimer's disease amyloid beta-protein and synaptic function. Neuromolecular Med. 2010 ; 12 (1). 13-26
124. Miller AH, Maletic V, Raison CL. Inflammation and its discontents: the role of cytokines in the pathophysiology of major depression. Biol Psychiatry. 2009 ; 65 (9). 732-741
125. Brodney MA, Johnson DE, Sawant-Basak A, et al. Identification of multiple 5-HT(4) partial agonist clinical candidates for the treatment of Alzheimer's disease. J Med Chem. 2012 ; 55 (21). 9240-9254
126. Steensland P, Fredriksson I, Holst S, et al. The monoamine stabilizer (-)-OSU6162 attenuates voluntary ethanol intake and ethanol-induced dopamine output in nucleus accumbens. Biol Psychiatry. 2012 ; 72 (10). 823-831
127. Jorge RE, Moser DJ, Acion L, Robinson RG. Treatment of vascular depression using repetitive transcranial magnetic stimulation. Arch Gen Psychiatry. 2008 ; 65 (3). 268-276